Molecular-based therapies for renal cell carcinoma

Current Urology Reports

Volumn 2, Issue 1, 2001, Pages 55-61

  Zisman, Amnon ^a   Pantuck, Allan J ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Human Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma; Renal Cell Carcinoma Cell Line; Renal Cell Carcinoma Patient

Indexed keywords

GENE THERAPY; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MOLECULAR BIOLOGY; REVIEW;

CARCINOMA, RENAL CELL; GENE THERAPY; HUMANS; KIDNEY NEOPLASMS; MOLECULAR BIOLOGY;

EID: 0035248312     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-001-0026-8     Document Type: Article

References (57)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JFJ: Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628–1631. DOI: 10.1001/jama.281.17.1628
2. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988, 48:7310–7313.
3. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995, 22:42–60.
4. Papac R: Spontaneous regression of cancer. Cancer Treat Rev 1996, 22:395–423. DOI: 10.1016/S0305-7372(96)90023-7
5. Garrido F, Ruiz-Cabello F: MHC expression on human tumors—its relevance for local tumor growth and metastasis. Semin Cancer Biol 1991, 2:3–10.
6. Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997, 80:1198–1220. DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H
7. Pierce WC, Belldegrun A, Figlin RA: Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin Oncol 1995, 22:74–80.
8. Gitlitz B, Hinkel A, Mulders P, et al.: Multi-antigen loaded dendritic cell (DC) vaccine for the treatment of metastatic renal cell carcinoma (mRCC)-in-vitro correlates. J Urol 1999, 161:137a. DOI: 10.1097/00005392-199904010-00550
9. Kugler A, Stuhler G, Walden P, et al.: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dentric cell hybrids. Nat Med 2000, 6:332–336. An excellent description of a milestone in the evolution of modern molecular-based therapies for metastatic RCC. This study sets the direction for dendritic cell tumor vaccines and novel molecule targeting. DOI: 10.1038/73193
10. Childs R, Chernoff A, Contentin N, et al.: Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem-cell transplantation. N Engl J Med 2000, 343:750–757. An excellent description of a milestone in the evolution of modern molecular-based therapies for metastatic RCC. DOI: 10.1056/NEJM200009143431101
11. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540.
12. Dutcher JP, Atkins M, Fisher R, et al.: Interleukin-2-based therapy for metastatic renal cell cancer: the cytokine working group experience, 1989–1997. Cancer J Sci Am 1997, 3 (suppl1):S73-S78.
13. Wirth M: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993, 20:283–295.
14. Saffran DC, Horton HM, Yankauckas MA, et al.: Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. Cancer Gene Ther 1998, 5:321–330.
15. Belldegrun A, Tso CL, Sakata T, et al.: Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. J Natl Cancer Inst 1993, 85:207–216. DOI: 10.1093/jnci/85.3.207
16. Seigne J, Turner J, Diaz J, et al.: Feasibility study of gene gun mediated immunotherapy for renal cell carcinoma. J Urol 1999, 162:1259–1263. DOI: 10.1016/S0022-5347(05)68260-2
17. Jung D, Hilmes C, Knuth A, et al.: Gene transfer of the co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 1999, 50:242–249. DOI: 10.1046/j.1365-3083.1999.00588.x
18. Gitlitz BJ, Belldegrun A, Figlin RA: Immunotherapy and gene therapy. Semin Urol Oncol 1996, 14:237–243.
19. Mulders P, Tso CL, Pang S, et al.: Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother 1998, 21:170–180. DOI: 10.1097/00002371-199805000-00002
20. Simons JW, Jaffee EM, Weber CE, et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colonystimulating factor gene transfer. Cancer Res 1997, 57:1537–1546.
21. Mulders P, Tso CL, Gitlitz B, et al.: Presentation of renal tumor antigens by human dendritic cells activates tumorinfiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999, 5:445–454.
22. Morelli S, Alama A, Quattrone A, et al.: Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line. Anticancer Drug Des 1996, 11:1–14.
23. Glenn GM, Linehan WM, Hosoe S, et al.: Screening for von Hippel-Lindau disease by DNA polymorphism analysis. JAMA 1992, 267:1226–1231. DOI: 10.1001/jama.267.9.1226
24. Linehan WM, Lerman MI, Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995, 273:564–570. DOI: 10.1001/jama.273.7.564
25. Ohh M, Kaelin WJ: The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today 1999, 5:257–263. DOI: 10.1016/S1357-4310(99)01481-1
26. Shuin T, Kondo K, Torigoe S, et al.: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852–2855.
27. Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85–90. DOI: 10.1038/ng0594-85
28. Anglard P, Tory K, Brauch H, et al.: Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 1991, 51:1071–1077.
29. Kovacs G, Emanuel A, Neumann HP, Kung HF: Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. Genes Chromosomes Cancer 1991, 3:256–262. DOI: 10.1002/gcc.2870030404
30. Foster K, Prowse A, van den Berg A, et al.: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994, 3:2169–2173. DOI: 10.1093/hmg/3.12.2169
31. Glavac D, Ravnik-Glavac M, Ovcak Z, Masera A: Genetic changes in the origin and development of renal cell carcinoma (RCC). Pflugers Arch 1996, 431:R193-R194. DOI: 10.1007/BF02346334
32. Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700–9704. DOI: 10.1073/pnas.91.21.9700
33. p, 17 and 22. Br J Cancer 1994, 69:230–234.
34. Ohta M, Inoue H, Cotticelli MG, et al.: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84:587–597. DOI: 10.1016/S0092-8674(00)81034-X
35. Iqbal MA, Akhtar M, Ali MA: Cytogenetic findings in renal cell carcinoma. Hum Pathol 1996, 27:949–954. DOI: 10.1016/S0046-8177(96)90223-3
36. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP: Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998, 58:226–231.
37. Chen F, Kishida T, Duh FM, et al.: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995, 55:4804–4807.
38. Lieubeau-Teillet B, Rak J, Jothy S, et al.: von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 1998, 58:4957–4962. An excellent description of a milestone in the evolution of modern molecular-based therapies for metastatic RCC.
39. Ananth S, Knebelmann B, Grüning W, et al.: Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999, 59:2210–2216. An excellent description of a milestone in the evolution of modern molecular-based therapies for metastatic RCC. This study sets the direction for dendritic cell tumor vaccines and novel molecule targeting.
40. Koshland DEJ: Molecule of the year [editorial]. Science 1993, 262:1953. DOI: 10.1126/science.8266084
41. Gottlieb TM, Oren M: p53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287:77–102.
42. Gottlieb TM, Oren M: p53 and apoptosis. Semin Cancer Biol 1998, 8:359–368. DOI: 10.1006/scbi.1998.0098
43. Qazilbash MH, Xiao X, Seth P, et al.: Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther 1997, 4:675–682. DOI: 10.1038/sj.gt.3300444
44. Oda H, Nakatsuru Y, Ishikawa T: Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995, 55:658–662.
45. Hupp TR, Meek DW, Midgley CA, Lane DP: Regulation of the specific DNA binding function of p53. Cell 1992, 71:875–886. DOI: 10.1016/0092-8674(92)90562-Q
46. Hupp TR, Sparks A, Lane DP: Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83:237–245. DOI: 10.1016/0092-8674(95)90165-5
47. Jayaraman J, Prives C: Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995, 81:1021–1029. DOI: 10.1016/S0092-8674(05)80007-8
48. Moon WC, Kim YS, Moon CS: Experimental p53 gene therapy in renal cell carcinoma. J Urol 1996, 155:653A. DOI: 10.1016/S0022-5347(01)66486-3
49. Schuler M, Rochlitz C, Horowitz JA, et al.: A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998, 9:2075–2082.
50. Swisher SG, Roth JA, Nemunaitis J, et al.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91:763–771. DOI: 10.1093/jnci/91.9.763
51. Oosterwijk E, Ruiter D, Hoedemaeker P, et al.: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986, 38:489–494. DOI: 10.1002/ijc.2910380406
52. Bander NH, Divgi C, Finn R, et al.: Renal cancer imaging with monoclonal antibody. J Urol 1996, 155:583A.
53. Drachenberg DE, Velasco A, Childs RW, et al.: G250 expression and von Hippel-Lindau mutation status in sporadic and hereditary renal cell carcinoma. Urologic Oncology 2000, Society of Urologic Oncology / National Cancer Institute, Narcner Conference Center, National Institutes of Health, Bethesda, MD, December 2–3, 2000.
54. Anton P, Tanke HJ, Allehoff EP, et al.: Localized renal-cell carcinoma: detection of abnormal cells in peritumoral tissue. A cytophotometry and immunocytochemistry study. World J Urol 1995, 13:149–152. DOI: 10.1007/BF00184869
55. van Dijk J, Uemura H, Beniers AJ, et al.: Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994, 56:262–268. DOI: 10.1002/ijc.2910560220
56. Zisman A, Pantuck A, deKernion J, et al.: G250-GM-CSF—a novel RCC specific tumor vaccine. AUA 95th Annual Meeting. Atlanta, Georgia, 2000:108. Important findings at the AUA Annual Meeting.
57. Rodriguez R, Simons J: Urologic applications of gene therapy. Urology 1999, 54:401–406. DOI: 10.1016/S0090-4295(99)00171-5